Your browser doesn't support javascript.
loading
PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment.
Thouvenin, J; Van Marcke, C; Decoster, L; Raicevic, G; Punie, K; Vandenbulcke, M; Salgado, R; Van Valckenborgh, E; Maes, B; Joris, S; Steichel, D Vander; Vranken, K; Jacobs, S; Dedeurwaerdere, F; Martens, G; Devos, H; Duhoux, F P; Rasschaert, M; Pauwels, P; Geboes, K; Collignon, J; Tejpar, S; Canon, J-L; Peeters, M; Rutten, A; Van de Mooter, T; Vermeij, J; Schrijvers, D; Demey, W; Lybaert, W; Van Huysse, J; Mebis, J; Awada, A; Claes, K B M; Hebrant, A; Van der Meulen, J; Delafontaine, B; Bempt, I Vanden; Maetens, J; de Hemptinne, M; Rottey, S; Aftimos, P; De Grève, J.
Afiliación
  • Thouvenin J; Hospices Civils de Lyon, Medical Oncology, Lyon, France; Institut Jules Bordet, Medical Oncology Clinic, Brussels, Belgium.
  • Van Marcke C; UCLouvain, Ottignies-Louvain-la-Neuve, Belgium.
  • Decoster L; UZ Brussel, Medical Oncology, Brussels, Belgium.
  • Raicevic G; Sciensano, Brussels, Belgium.
  • Punie K; KU Leuven University Hospitals Leuven, General Medical Oncology, Leuven, Belgium.
  • Vandenbulcke M; Sciensano, Brussels, Belgium.
  • Salgado R; GasthuisZusters Antwerpen, Pathology, Antwerp, Belgium.
  • Van Valckenborgh E; Sciensano, Brussels, Belgium.
  • Maes B; Laboratory of Molecular Diagnostics, Jessa Hospital Campus Virga Jesse, Hasselt, Belgium.
  • Joris S; UZ Brussel, Medical Oncology, Brussels, Belgium.
  • Steichel DV; Fondation contre le Cancer, Schaerbeek, Belgium.
  • Vranken K; Pediatric Oncology, WIV-ISP, Leuven, Belgium.
  • Jacobs S; KU Leuven Hospital, Leuven.
  • Dedeurwaerdere F; Laboratory of Pathology, AZ Delta, Roeselare, Belgium.
  • Martens G; Laboratoriumgeneeskunde, AZ Delta, Roeselare, Belgium.
  • Devos H; Laboratoriumgeneeskunde, AZ Sint-Jan, Bruges, Belgium.
  • Duhoux FP; UCLouvain, Ottignies-Louvain-la-Neuve, Belgium.
  • Rasschaert M; Universitair Ziekenhuis Antwerpen, Medical Oncology, Antwerpen, Belgium; Medical Oncology, AZ Monica, Deurne, Belgium.
  • Pauwels P; Universitair Ziekenhuis Antwerpen, Pathology, Antwerpen, Belgium.
  • Geboes K; Division of Digestive Oncology, Department of Gastroenterology, UZ Gent, Gent, Belgium; Department of Internal Medicine and Pediatrics, UZ Gent, Gent, Belgium.
  • Collignon J; Medical Oncology, CHU de Liege - Hospital Sart Tilman, Liège, Belgium.
  • Tejpar S; KU Leuven Hospital, Leuven.
  • Canon JL; Grand Hôpital de Charleroi Site Notre Dame, Service d'Oncologie-Hématologie, Charleroi, Belgium.
  • Peeters M; Universitair Ziekenhuis Antwerpen, Oncology, Antwerpen, Belgium.
  • Rutten A; GZA Ziekenhuizen Campus Sint-Vincentius, Medical Oncology, Antwerpen, Belgium.
  • Van de Mooter T; GZA Ziekenhuizen Campus Sint-Vincentius, Medical Oncology, Antwerpen, Belgium.
  • Vermeij J; ZNA Middelheim, Medical Oncology, Antwerpen, Belgium.
  • Schrijvers D; ZNA, Antwerpen, Belgium.
  • Demey W; AZ Klina, Medical Oncology, Brasschaat, Belgium.
  • Lybaert W; GZA Ziekenhuizen Campus Sint-Vincentius, Medical Oncology, Antwerpen, Belgium.
  • Van Huysse J; AZ Sint-Jan Brugge-Oostende, Pathology, Brugge, Belgium.
  • Mebis J; Laboratory of Molecular Diagnostics, Jessa Hospital Campus Virga Jesse, Hasselt, Belgium.
  • Awada A; Institut Jules Bordet, Medical Oncology Clinic, Anderlecht, Belgium.
  • Claes KBM; UGent, Gent, Belgium.
  • Hebrant A; Sciensano, Brussels, Belgium.
  • Van der Meulen J; UGent, Gent, Belgium.
  • Delafontaine B; UZ Gent, Gent, Belgium.
  • Bempt IV; KU Leuven Hospital, Leuven, Belgium.
  • Maetens J; Sciensano, Brussels, Belgium.
  • de Hemptinne M; Sciensano, Brussels, Belgium.
  • Rottey S; Medical Oncology Department, UZ Gent, Gent, Belgium.
  • Aftimos P; Institut Jules Bordet, Medical Oncology Clinic, Anderlecht, Belgium.
  • De Grève J; UZ Brussel, Medical Oncology, Brussels, Belgium. Electronic address: Jacques.degreve@uzbrussel.be.
ESMO Open ; 7(4): 100524, 2022 08.
Article en En | MEDLINE | ID: mdl-35970014
ABSTRACT
PRECISION is an initiative from the Belgian Society of Medical Oncology (BSMO) in collaboration with several stakeholders, encompassing four programs that aim to boost genomic and clinical knowledge with the ultimate goal to offer patients with metastatic solid tumors molecularly guided treatments. The PRECISION 1 study has led to the creation of a clinico-genomic database. The Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT) and GeNeo studies will increase the number of patients with advanced cancer that have comprehensive genotyping of their cancer. The PRECISION 2 project consists of investigator-initiated phase II studies aiming to provide access to a targeted drug for patients whose tumors harbor actionable mutations in case the matched drug is not available through reimbursement or clinical trials in Belgium.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Medicina de Precisión / Neoplasias Tipo de estudio: Prognostic_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: ESMO Open Año: 2022 Tipo del documento: Article País de afiliación: Bélgica
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Medicina de Precisión / Neoplasias Tipo de estudio: Prognostic_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: ESMO Open Año: 2022 Tipo del documento: Article País de afiliación: Bélgica